Clinical Trial Update: Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating sacituzumab govitecan in metastatic castration-resistant prostate cancer that progressed on second-generation AR-directed th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Sacituzumab Govitecan (Trodelvy) (sacituzumab govitecan)

Snippet

Sponsor: University of Wisconsin, Madison | Conditions: Prostate Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-04-24